NanoLogix Inc (NNLX)

[All City Baby]

Company Updates


Nov. 24, 2020

Rapid COVID19 Test Patent Granted

Full details of the granted patent, with the complete list of twenty-five granted claims are available in the USPTO Patent Gazette publication

We are pleased to announce the patent for rapid viral testing and diagnosis has been granted and issued by the United States Patent and Trademark Office (USPTO) with a US patent number of 10844442. Information on the published patent can be accessed in the USPTO Official Gazette for Patents and entering the patent number through this link:

http://patentsgazette.uspto.gov/week47/OG/patent.html

There are many extremely vital aspects to this technology. In addition to very accurate and rapid detection of the COVID19 Spike Protein and Virion, another essential capability of the assay is its ability to rapidly detect the presence of the neutalizing antibody to the virus, a quality that can determine both the need for vaccination and the effectiveness and longevity of the neutralizing antibodies. Development work on the technology has indicated potential detection times of twenty minutes or less.

An international patent application under the Patent Cooperation Treaty (PCT) and a Continuation In Part (CIP) were filed this past weekend to provide international patent protection by broadening the geographic and technological scope of the Intellectual Property protection and to add additional aspects to the technology that have been discovered or invented since the original application date.

A formal Press Release will be issued next week after the Thanksgiving Holiday weekend.


Nov. 11, 2020

Rapid COVID19 Test Patent Update

Patent filed May 18 Grant and Issuance will Occur within Two Weeks

We are pleased to announce the patent for rapid viral testing and diagnosis is scheduled for grant and issuance by the United States Patent and Trademark Office (USPTO) in less than two weeks. Information on the patent should be published in the USPTO Official Gazette for Patents on November 24th. Prior to that date both an international patent application under the Patent Cooperation Treaty (PCT) and a Continuation In Part (CIP) will be filed to broaden both the geographic and technological scope of the Intellectual Property protection and to add additional aspects to the technology that have been discovered or invented since the original application date.

Full details of the granted patent, with the complete list of twenty-five granted claims will be available upon Gazette publication.


Oct. 28, 2020

Narrative of Some Issues Faced By NanoLogix Since May Announcement of Rapid COVID19 test

Issues are Resolved and NanoLogix Is Proceeding with Technology Development and Awaiting the Allowed Patent Issuance

Appreciation to Congressman Tim Ryan for his Interest and Assistance in Resolution

NanoLogix is presenting this narrative to illustrate the unusual and unanticipated challenges that were presented to the Company beginning immediately after our announcement of the invention and the initial results for a rapid viral detection test technology applicable to COVID-19 and other viruses.

Within a few days of our May 3rd announcement covering this news, we were reported by an unknown party or parties to FINRA, the FDA, and the SEC.

During the course of these events, and until their resolution, we did not believe we could approach investors for funding necessary for the further development of the technology. Nor could we seek development partners until this "Matter" was resolved. NanoLogix was delayed and blocked for approximately five months until the resolution of the "Matter" with no action recommended.

For the full narrative, please follow this link:

https://nanologix.com/narrative-of-some-issues-faced-by-nanologix-since-may-announcement-of-rapid-covid19-test-and-since-resolved/


Oct. 14, 2020

NanoLogix Is Researching FDA EUA Requirements For COVID-19 Testing Related to Recently Allowed Patent

1st For Whole Virus Detection, 2nd For Antibody Detection

NanoLogix Welcomes David R. Barnhizer as Vice President For Strategic Analysis and Development

NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics.

Upon successful results for work currently being performed by a third party to apply NanoLogix technology to a separate testing platform for COVID19 detection, other applications may follow. Once the patent is issued we will reveal the broad and detailed extent of allowed claims for this technology.

Within the next two weeks NanoLogix will be releasing a narrative detailing challenges that were presented to the Company from outside sources apparently opposed to either the technology development or the Company since our May release of the COVID19 news.

David Barnhizer is Professor of Law Emeritus at the Cleveland State University. He received law degrees from the Ohio State University where he graduated summa cum laude and from Harvard University where he was a Ford Foundation Urban Law Fellow, a CLEPR Clinical Teaching Fellow, and earned a Masters of Law degree. He was Articles Editor of the Ohio State Law Journal, and began his legal career as a Reginald Heber Smith Community Lawyer in Colorado with the Colorado Springs Legal Services Office.

He has been a Senior Research Fellow at the University of London's Institute for Advanced Legal Studies, a frequent Visiting Professor at the Westminster University School of Law in London, taught human rights and international environmental law in St. Petersburg, Russia in a joint program with St. Petersburg State University, and instructed in Harvard’s Intersession program in Trial Advocacy.

He has served as Senior Adviser in the International Program of the Natural Resources Defense Council (NRDC). He was a Senior Fellow with Earth Summit Watch, and a board member of the International Shrimp Action Network (ISANET) an international NGO network made up of more than twenty NGOs involved in environment, development and coastal zone management in developing countries. He was Executive Director of the Washington, DC-based Year 2000 Committee, and has consulted extensively with environmental and development organizations. These include the World Resources Institute, the International Institute for Environment and Development, the United Nations Development Program, the President’s Council on Environmental Quality, the World Bank, the United Nations Food and Agricultural Organization (FAO), the World Wildlife Fund, the Mongolian government, and the Center for Global Change.

In addition, he spent nine years as a member of the board of directors for Performance Capital Management, and was a strategic consultant for Sovonics Solar Systems, a subsidiary of British Petroleum. He also served as Rapporteur for the Foresight Capability Workshop of the Energy and Commerce Committee of the US House of Representatives and has worked on projects in conjunction with numerous federal agencies.

He has written over fifty law review articles and book chapters, and authored and edited a number of books, including The Warrior Lawyer, a work developing the strategic principles of Sun Tzu's Art of War and Musashi's A Book of Five Rings. Other books include Strategies for Sustainable Societies, Environment Cleveland, The Blues of a Revolution, two volumes on Effective Strategies for Protecting Human Rights, and Hypocrisy & Myth: The Hidden Order of the Rule of Law co-authored with Daniel Barnhizer.

The most recent book, co-authored with Michigan State University Professor of Law Daniel Barnhizer, is The Artificial Intelligence Contagion: Can Democracy Withstand the Imminent Transformation of Work, Wealth, and the Social Order? CONTAGION has been ranked as high as # 1 in Book Authority’s All-Time Top 100 books on Robotics and in the top ten in Book Authority’s All-Time list on artificial intelligence.


Oct. 8, 2020

NanoLogix Notified of Patent Allowance for Sub 1-Hour Covid-19 Detection Technology

Allowance for All 25 Patent Claims Issued September 8th, 3-1/2 months after May 18th Filing Date

Additional and related news to be released next week.


Oct. 5, 2020

NanoLogix Covid-19 Detection Test Update

Partial Funding received from NanoLogix Directors Options Exercise

NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance

The Directors' action reflects their belief in the NanoLogix rapid viral detection technology and its potential.

Independent laboratory work in Houston on a separate phase and aspect of the testing technology will begin after initial results from the above-mentioned work.


Aug. 7, 2020

NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments

NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory

NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.

The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.

While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.

NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.


June 11, 2020

Sub-1-Hour Covid-19 Detection Technology Patent Pending Update

NanoLogix is pleased to announce we have received a notification, dated 06/03/20, from the US Patent and Trademark Office stating the application has been granted Prioritized Status under the new COVID-19 Prioritized Examination Pilot Program?.

"1. THE REQUEST FILED 18 May 2020 IS GRANTED.

The above-identified application has met the requirements for prioritized examination

A. For an original nonprovisional application (Track I).

2. The above-identified application will undergo prioritized examination. The application will be accorded special status throughout its entire course of prosecution..."

The significance of the USPTO granting of Prioritized Status is that the evaluation of the patent application under the new COVID-19 Prioritized Examination Pilot Program has been completed and the application has been accepted into the program. This Program has been initiated by the USPTO as a response to the Pandemic Crisis. We suggest readers access the USPTO and Federal Register link at the bottom of this update in order to fully understand the significance of the program.

In addition, NanoLogix is, and has been, in talks with multiple diagnostic and financial companies regarding development and potential partnering for use of the Rapid Viral Assay against the COVID-19 virus.


June 3, 2020

NanoLogix Seeks Development & Marketing Partner for Their Sub 1-Hour COVID-19 Detection Tests

HUBBARD, Ohio, June 3, 2020 /PRNewswire/ -- NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can also be configured for other viruses, such as, but not limited to, HIV, HPV, Hepatitis, MERS, and SARS-1. A Home-Test version of the COVID-19 test has the potential of 30-minute results using a nasopharyngeal swab or saliva samples.

CEO Bret Barnhizer stated: "NanoLogix does not possess the scale of production or marketing required for this essential test distribution for COVID-19. We cannot expand rapidly enough to meet the immediate need for testing. We have entered into Confidentiality Agreements with two diagnostic and financial groups in the last week for this purpose and are inviting additional interest."

Jonathan Faro, MD, PhD., Chief Medical Officer stated: "We are extremely excited over this technology development. It is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."


May 31, 2020

NanoLogix and COVID-19 Testing News

Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May.

Warren Tribune:

https://www.tribtoday.com/news/local-news/2020/05/hubbard-based-nanologix-creates-rapid-covid-19-test/

Youngstown Vindicator:

https://www.vindy.com/opinion/brenda-j-linert/2020/05/all-roads-still-lead-to-the-mahoning-valley/

Youngstown Vindicator:

https://www.vindy.com/news/local-news/2020/05/fast-test-detects-variety-of-viruses/

Channel 27 (CBS) Youngstown:

https://www.youtube.com/watch?v=LrPoqVAH1No

Fox News 13 Tampa:

https://www.youtube.com/watch?v=HVcSchmwXgc

The Youngstown Vindicator is now published by the Warren Tribune, so while we link to one example, duplicate articles can be found for the same dates for both newspapers.


May 29, 2020

NanoLogix Rolls Out New Website With COVID-19 Testing Information

NanoLogix is pleased to announce their new website at www.nanologix.com. In visiting the website, please take note of the new PowerPoint titled: "Testing for COVID-19: Why current testing strategies don’t work" authored by Jonathan Faro, MD, PhD., and James Rogers, PhD., clearly presenting the reasons why the new NanoLogix COVID-19 detection technology is essential.

The Company is in the process of increasing its filled Petri plates product offerings with revised pricing on the Purchase Page so those pages are listed as under construction. That status will end in a few days and anyone currently needing to order can contact the Company directly. We continue to accept orders via email and phone.


May 18, 2020

NanoLogix Sub 1-Hour Covid-19 Detection Test Now Patent-Pending

Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program

NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.

This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.

While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".

An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.

Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."

The US Patent Office program under which the filing was done can be accessed through the following link:

https://www.federalregister.gov/documents/2020/05/14/2020-10372/covid-19-prioritized-examination-pilot-program


May 3, 2020

NanoLogix Develops Sub 1-Hour Coronavirus 19 Detection Technology and Welcomes James Rogers, PhD as Chief Science Officer

Last week NanoLogix completed development testing of a unique Coronavirus (COVID-19) detection technology with sub 1-hour results and exceptional sensitivity and accuracy. The technology has the potential to be configured as a Point of Care (POC) and also for individual consumer use. The development work was performed in the NanoLogix Laboratory in Hubbard, Ohio. More information on the technology will be released in the near future in a formal press release.

----------------------

James Rogers, PhD, has more than 20 years of biomedical research experience within U.S. Government, contract research organization, and biotechnology industries. This experience includes serving as a Study Director, Principal Investigator, Subject Matter Expert (SME), and Operations Manager executing studies supporting research and development, testing and evaluation, preclinical, and clinical support studies.

From his more than 15 years working at Battelle, Dr. Rogers brings vast experience specializing in the testing and evaluation of medical countermeasures for biological and chemical threat agents. This experience includes transcriptomics/bioinformatics, microRNA analysis, and immunological techniques to investigate biochemical pathways underlying host responses as well as the identification of biomarkers and potential therapeutic targets. He led the development and qualification/validation of several molecular and immune assays to support immunogenicity evaluation, biodistribution studies of vaccines, and clinical trials. He also served as the SME and Program Director for projects that included persistence and decontamination of biological/chemical agents, diagnostic kit and detector testing, and immunotoxicology.

Dr. Rogers received his PhD in Biomedical Sciences from Wright State University, focusing on skin immunology and DNA vaccines. He worked as a post-doc for Geo-Centers, Inc. within the U.S. Air Force Research Laboratory at Wright-Patterson Air Force Base. His research focused on molecular mechanisms associated with volatile organic chemical-induced skin irritation using three-dimensional in vitro and in vivo models.

Dr. Rogers is an author on more than 60 scientific publications and book chapters, presented at national scientific meetings, actively serves on multiple scientific journal Editorial Boards, and served as Book Editor of Microarrays: Principles, Applications and Technologies (Nova Science Publishers, 2014).

----------------------

Dr. Rogers has been significantly involved in our development of the Coronavirus 19 detection technology. He is also the lead author on multiple peer-reviewed published research papers on NanoLogix technologies from his time at Battelle Biomedical Research Center. We at NanoLogix are extremely grateful to have him join our Team and look forward to a very positive future.


Mar. 24, 2020

NanoLogix Update - COVID-19 Second Hospital Donation

Brief note from Nanologix to its shareholders:

This morning the CEO of NanoLogix, on behalf of the Company, donated an additional 2,000 examination gloves to the Emergency Room staff at St. Elizabeth Hospital in Youngstown, Ohio for their use during the current COVID-19 crisis. They were received by the Nursing Manager at the ER who said they are appreciated and will be a great help to the staff.


Mar. 20, 2020

NanoLogix Update - COVID-19 Hospital Donation

Brief note from Nanologix to its shareholders:

This morning the CEO of NanoLogix, on behalf of the Company, donated 100+ surplus lab/protective coveralls and 1300 examination gloves to the Emergency Room staff at St. Elizabeth Hospital in Youngstown, Ohio for their use during the current COVID-19 crisis.


Mar. 15, 2020

NanoLogix Update - COVID-19 Detection

Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.

We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.

NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.

We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.

We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.

A recap of our late-February Update:

While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.

The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.

In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.


Feb. 28, 2020

Response to Coronavirus Queries both International and US

The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.

While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.

In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.


Jan. 31, 2020

Response to Coronavirus Questions From Shareholders

Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:

Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak, we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities.


Jan. 14, 2020

NanoLogix PreTest Development Update

NanoLogix is pleased to provide an additional update on the Screening/Pretest and its potential as a standalone test.

An important aspect of the Bacteria and Yeast pretest revealed during Phase One development is the ability to detect and specifically identify Candida yeast infection in human fluids, with no cross-reactivity from other microorganisms. The importance of this is three-fold. The first aspect is that this Candida test is a FIVE-MINUTE TEST. The second is that it can be offered for consumer use in retail outlets, in addition to being used by clinicians for laboratories and medical offices. The third is that there is no other consumer test that specifically identifies Candida, and in doing so, we believe it will provide the ability for consumers to self-diagnose and treat a condition that affects a large percentage of the public.


Dec. 16, 2019

NanoLogix Update on Phase One PreTest Development

NanoLogix is pleased to provide an update on the development of a Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.

The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).

This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.

This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.

The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.

In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.

A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.

A direct link to the PowerPoint is here:

http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx

It is also available on our website at:

http://nanologix.com/

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.


Oct. 14, 2019

NanoLogix Provides Update on Development

NanoLogix is pleased to provide this brief update on the development on the N-Assay Bacteria Diagnostic Screening/Pretest. The development work in the UK by a company with Global operations began on October 1st and is in the first of four phases that will carry through to patient studies in Houston planned for 2020. This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI (Urinary tract infections) projected for 2021.

The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.

In step with the development plans, NanoLogix has requested assistance from the Youngstown State University's Career Center in locating and hiring two laboratory personnel for our Ohio Lab. These personnel will configure the N-Assay Diagnostic tests to conform with the results and efforts of the UK development company.


Aug. 21, 2019

NanoLogix Seeks $3 Million For Expansion and Development

Offers Net-Revenue Share of N-Assay Bacteria Diagnostic

NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.


Apr. 30, 2019

Enhanced Update on N-Assay

Overview and Potential in Multi-billion Dollar Diagnostics Market

NanoLogix has updated an important PowerPoint Presentation on the N-Assay Bacteria Diagnostic. The update includes additional information on Upper Repiratory Infections (URI), general Sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.


Apr. 2, 2019

Update on N-Assay

Overview and Potential in Multi-billion Diagnostics Market

NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.

The PowerPoint Presentation can be viewed on the NanoLogix website at: http://nanologix.com/.



The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.


Jan. 16, 2019

Update on N-Assay Pretest Development

NIH Grant Application Submitted for Pre-test Development Study

NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recommendation from noted medical authorities written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.

The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.

The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.

The current focus of this NIH grant application is on Group B Streptococcus (GBS). We are currently discussing Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.

NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.

Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.


Dec. 19, 2018

Nigeria FlatPack Patent Granted

NanoLogix is extremely pleased to have received notification of grant from the patent firm of Spoor and Fisher of the acceptance and grant in Nigeria for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

This Nigeria patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, Mexico, and the European Union.

Efforts are ongoing for both license and/or sale of the FlatPack rights in countries outside of the USA, with varied levels of interest from manufacturers.

A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf

For reference, this patent took nearly 7-1/2 years to be issued from the date or Patent Cooperation Treaty (PCT) filing.


Oct. 26, 2018

N-Assay Summary for upcoming NanoLogix Website

New write up that will be posted on our new website soon for our patented diagnostic. Comments and interest welcomed:

Nanologix' N-Assay offers an innovative solutions to a major problem that has plagued physicians over the years.

In medicine, nothing gets a clinician's attention like sepsis. When one has seen a patient who had previously been doing just fine suddenly take a turn for the worse, management decisions must be made without hesitation. In the case of a septic patient, seconds mean the difference between life and death, and minutes are a luxury that neither the clinician nor the patient may afford. The post-operative patient, the post-partum patient, the ICU patient... any patient is at risk of encountering a virulent pathogen in the hospital, and without an astute clinician ready to respond, serious consequences will occur. It's not surprising that the Infectious Disease Society of America estimates just this year that treating infections cost 21 to 34 billion dollars annually, in the US alone.

Clinicians currently have two techniques at their disposal when treating a presumed infection -culture, and PCR. The traditional technique of culture is labor intensive, requires laboratory-trained personnel, and correctly obtained, viable material. Although this method is relatively inexpensive, it is incredibly time-consuming. Patients often find it hard to believe that obtaining a culture result and antibiotic sensitivity profile may take 5 days! While the clinician is waiting for the results, they are throwing everything they've got at the possible infection. This is truly an empiric approach, and here it pays to have an experienced clinician by your side.

The alternative method, PCR, is much faster, much more sensitive, but also much more expensive. This newer technique also costs a great deal more, and requires highly trained personnel to operate the devices. These machines also incur a large capital investment by the hospital, as well as annual maintenance. In spite of the strengths of PCR, it also has weaknesses -it is unable to differentiate the difference between live/dead bacteria, and can not provide estimates relating to the degree of the inoculum. This information is essential for the clinician in directing targeted therapy, so again, they are ultimately forced to rely on their experience when treating the patient.

Regardless of one's opinion as to whether culture or PCR is the better option, the data over the last few decades shows the depressing truth -neither option is offering us any real advantage. This is made clear when one looks at the development of antibiotic resistance. These bugs have continued to grow and evolve, and a few years ago, a gonorrhea "super-bug" was isolated -showing resistance to every antibiotic available. We are clearly losing the war against these single-cell enemies!

In answer to this major problem, we have developed and patented an approach that takes all of the advantages of both culture and PCR (specificity, sensitivity, speed, and accuracy as well as ease of use), and none of the disadvantages. This technique, termed the N-Assay, is an antibody-based assay that targets potentially any bacterial pathogen (and has also been seen to detect yeast), in as little as 30 minutes. In addition, when incubated for 6 hours, this test not only provides a bacterial identification, but also allows the clinician to determine which antibiotic will work in treating the infection. This test will dramatically shorten the amount of time required for a clinician to wait when treating the ill patient, and should ultimately save billions in healthcare spending. Furthermore, by more accurately targeting the right bacterium with the correct antibiotic, we should drastically reduce the incidence in antimicrobial resistance.

We have already used a pilot version of this test in detecting group B streptococcus colonization in pregnant women, and have won an award at an OB GYN conference when presenting our data. The clinicians see that this test has tremendous potential, and are eager for it to be available, as they simply need better methods to more accurate diagnose infection. With the right resources, we will be able to expand this test to additional bacterial pathogens, such as E. coli, Enterococcus, MRSA, and any other clinically relevant pathogen.


Sept. 7, 2018

Notice of Upcoming NanoLogix Website Revision

Request For Confirmation of Continuing Interest From Newsletter Subscribers

NanoLogix is pleased to announce the Company website will be extensively revised and updated during September and October. The Company requests that those Newsletter Subscribers who are interested in continuing to receive updates of NanoLogix news through our iContact news service to send a confirmation email to: [e-mail]

This revision will enable the Company to significantly improve the website, providing the ability to respond rapidly to business events and to quickly furnish business, technology, and hospital study updates.


Aug. 20, 2018

NanoLogix Attends Series of Meetings In Houston

Preparation for Pre-test Development Study

NanoLogix is pleased to announce their attendance at a series of meetings in Houston with Drs. Sebastian and Jonathan Faro and the CEO of a California-based Biotechnology firm. The purpose of the meetings was for coordinating forces for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic. The meetings dealt with organization and staffing of a research study at two major Houston hospitals, funded from both Federal Grants and a raise of investment capital, and the specific personnel required for the successful execution of the study. The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.

The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.

NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.

Dr. Jonathan Faro, PhD, MD stated: "These are incredibly exciting times for Nanologix. Seeing this study begin to crystallize has been invigorating, and it's wonderful to see other health care providers share an interest in our test, which is the leading diagnostic assay in bacterial identification and determination of antibiotic susceptibility. When speaking with nurses and other doctors, it's extraordinary to see their enthusiasm for the test --- we have found the right home for a study of this magnitude."


July 16, 2018

NanoLogix Welcomes Dr. Jonathan Faro to Board of Directors

Jonathan Faro, PhD, MD, joins as Director of Medical Development

NanoLogix is pleased to announce the addition of Jonathan Faro, PhD, MD to the Company's Board of Directors. Dr. Faro is the co-inventor of the N-Assay modified ELISA bacteria-detection and identification technology and primary author of a number of published peer-reviewed research papers on the technology.

Dr. Faro's statement:

I am very excited to have joined the Board of Directors at NanoLogix, Inc. As the Director for Medical Development, I will serve a direct role in advocating for the goals of the company, and plan to work alongside the CEO and other boardmembers to further development of the N-Assay. With their support, I have several goals that I aim to achieve. First and foremost, several studies need to be initiated. In addition to a large, multi-site study involving both private and academic centers, we will work on establishing multiple small-scale studies. Each of these will focus on the unique strengths of the N-Assay, so that clinicians will see that the assay is superior to anything currently on the market. We will focus on a four-pronged approach:

A) Speed of pathogen identification, providing clinicians with an accurate result far faster than that of culture,

B) Determination of antimicrobial resistance, so that clinicians may target their approach quickly, and begin seeing results faster than with any other technology on the market.

C) Offer clinicians novel approaches in treating infectious diseases, so that we stop the continued development of antimicrobial resistance.

D) Offer cheaper tests that do not increase the burden on national and international healthcare resources.

This final goal will have the benefit of taking NanoLogix not just through the US market, but will allow it to gain steady footing in the global market, which is necessary in order to truly help in limiting the spread of antimicrobial resistance, which currently claims approximately 700,000 lives per year. Although each of these goals will require considerable time, effort, and financial support, we have already begun the process of building in-roads with multiple well-respected clinical collaborators. These next several months certainly will be very exciting times for both myself and for NanoLogix!


Apr. 19, 2018

Update On Petri FlatPack International Patent Status

Pursuant to NanoLogix' International Patent Offering

NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.

Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.


Apr. 11, 2018

Further European Patent Office Information on FlatPack Patent for Sale and Licensing

International Patent Offering

NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.

Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".

Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".

The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.

The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:

Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.

Pending: Brazil, Canada


Nov. 27, 2017

Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application

International Patent Offering

NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.

Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.

For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.

Central Association of Obstetricians and Gynecologists

Dr. Jonathan Faro, PhD, MD presented the following poster at the CAOG Annual Meeting in Scottsdale, Arizona:



NanoLogix and the authors are in agreement on the need for a rapid definitive diagnostic for UTI and the N-Assay and its soon to be developed screening pre-test are the needed tools to fill the projected need.

National Science Foundation Grant Application

NanoLogix, the Houston medical personnel involved in the N-Assay development and a professional grant writer are finalizing a grant application for $1,500,000.00 from the NSF for funding of both development of a screening ‘pre-test” to be used in conjunction with the N-Assay and also finalization for marketing of the N-Assay. Link to what is offered by the NSF can be found here:

https://seedfund.nsf.gov

While there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.


Sept. 1, 2017

Tropical Storm Harvey and FlatPack Update

NanoLogix is donating 1,000 specialized petri plates in 100 FlatPacks of ten plates each to a major hospital in Houston for their use in testing for contamination caused by flooding in their facility. As electrical power loss has been significant in the area a major determining factor in the selection by hospital staff was the ability of our FlatPack petri plates to be stored at room temperature for extended periods, while other manufacturers' products must be refrigerated. This highlights just one of the many qualities of the argon-flushed FlatPack vacuum packaging for petri plates.

The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf


Aug. 31, 2017

EU, Hong Kong & PRC FlatPack Update

NanoLogix is pleased to announce initial interest from both the EU and PRC areas in the offer for sale of the Flatpack patents for those areas.

To maintain rights for the near future in various EU patent agreement signatory countries while awaiting firm commitments for sale, we are paying the registration fees for the FlatPack patent in the following 14 countries:

Croatia
Denmark
France
Germany
Italy
Ireland
The Netherlands
Poland
Serbia
Spain
Sweden
Switzerland/Lichtenstein
Turkey
The UK

The fees for the 14 countries are approximately $30,000 USD.

The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf

The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.

The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.


Aug. 2, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology To Be Presented Today at AACC Annual Meeting in San Diego

The N-Assay Diagnostic is a novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of Deinococcus Bacteria. The following information is being presented today at the American Association for Clinical Chemistry (AACC) 69th Annual Meeting in San Diego:



The significance of the results shown in the presentation cannot be overstated, as with the addition of the Deinococcus results listed, the N-Assay now has demonstrated its applicability across a broad spectrum of bacteria which to date include E.coli, Group B Streptococcus, Enterococcus, and Gonorrhea, in addition to the yeast Candida.

Dr.Jonathan Faro, PhD, MD, tweeted the following two messages yesterday:

"Excited to be at AACC 2017! Over 20,000 registrants and lots of great exhibits!"

"Having a great time at AACC 2017! Getting a lot out of the exhibits. Lots of exciting new technology, but nothing close to the N-Assay!"

You may follow this link to the AACC information website:

https://www.aacc.org/meetings-and-events/2017-annual-meeting


July 12, 2017

NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million

HUBBARD, Ohio, July 12, 2017 (GLOBE NEWSWIRE) -- NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (B)) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.

The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.

The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf

The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.

Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.


July 5, 2017

Mexico FlatPack Patent Granted

NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.

A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf

For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.


June 22, 2017

EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale

NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf

The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.

The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.


June 8, 2017

EU & Hong Kong FlatPack Patent Issued

NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.

A PDF of the issued patent may be viewed here:

http://www.freepatentsonline.com/EP2699491.pdf

A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:

http://medcraveonline.com/JMEN/JMEN-03-00075.pdf

NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.

For reference: The patent process from the date of filing to issuance took five years and two months.


June 5, 2017

Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting

Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:

"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."

Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.

The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.

Two published examples of the N-Assay and its performance can be accessed through the following links:

https://www.hindawi.com/journals/idog/2016/5293034/

http://nanologix.com/news/poster-e-coli-0157.pdf

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.


June 2, 2017

Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans

Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.

http://nanologix.com/news/poster-e-coli-0157.pdf

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.


June 1, 2017

NanoLogix TB Detection Technology Use on Africa Project Increases

NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.

This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.

For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:

https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html

Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."


May 19, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract

Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

Novel Immunoassay for E coli O157:H7

Researchers: Classified until June 2017

Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.

Methods: N-ASSAY

Methods Details Classified until June 2017

Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.

Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.


May 8, 2017

Additional TB Test Kits ordered for Third World Gates Foundation Project

NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.

Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.

The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:

https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html

Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.

In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.


May 4, 2017

TB test Kits for use in Third World Gates Foundation Project

NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.

Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.

The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.

The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.

...and now we've sold TB diagnostics for use on a project funded by whom...?

Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.

We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.


Apr. 28, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:

NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.

NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.

The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.

The published research results may be accessed through this link:

http://dx.doi.org/10.1155/2016/5293034

The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.

Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:

https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo

The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:

https://www.asm.org/index.php/asm-microbe-2017


Apr. 4, 2017

NanoLogix has shipped TB test Kits for use in Third World Project

NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.


Mar. 16, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:

NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.

NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.

Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.


Mar. 2, 2017

NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:

After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.

Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.

There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.


Jan. 9, 2017

NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:

The N-Assay takes its place on our FDA medical device listing:

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB

There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.

NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.


Dec. 20, 2016

NanoLogix is pleased to announce the following Update:

The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.

This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.

Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.

Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.

The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.

In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.

Merry Christmas from Carol, Debby, Kim, Travis, Bret and all.


Dec. 6, 2016

NanoLogix is pleased to announce the following Update:

The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.

The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.

NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.

The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com

The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.

The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.

The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.

Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.


------------------------------------------------------------------------------------------------------------------------------

Updates are available by signing up for eNews on the company's homepage at nanologix.com.